Market Place
Sourcing Support
Caliway Gets EMA Orphan Designation for CBL-514 in Dercum’s Disease
12 Nov 2024 //
PR NEWSWIRE
Caliway Completes CBL-514 Ph 2b Study For Subcutaneous Fat Reduction
23 Oct 2024 //
PR NEWSWIRE
Caliway Begins Recruitment for CBL-514 Phase 2b Study for Dercum`s Disease
03 Sep 2024 //
PR NEWSWIRE
Caliway To Present At BIO International Convention 2024
11 May 2024 //
PR NEWSWIRE
Caliway Announced Orphan Drug Designation Granted to CBL-514
03 Mar 2024 //
PR NEWSWIRE
Caliway Received U.S. FDA Fast Track Designation for CBL-514
14 Feb 2024 //
PR NEWSWIRE
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application
23 Jan 2024 //
PR NEWSWIRE
Caliway Announces FDA Acceptance of CBL-514 IND Application
08 Jan 2024 //
PR NEWSWIRE
Caliway to Present CBL-514 Phase 2 Study Results for Subcutaneous Fat Reduction
26 Dec 2023 //
PR NEWSWIRE
Caliway Closes Oversubscribed Capital Raise and Secures Over $100M
16 Dec 2023 //
PR NEWSWIRE
Caliway`s CBL-514 Achieved Better Efficacy than Liposuction
02 Oct 2023 //
PR NEWSWIRE
Caliway Announces the Completion of Phase 2-stage 2 Study Evaluating the CBL-514
18 Sep 2023 //
PR NEWSWIRE
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum`s Disease
13 Sep 2023 //
PR NEWSWIRE
Caliway Announces Positive Data from CBL-0201EFP Ph 2-Stage 1 Study of CBL-514
28 Jun 2023 //
PR NEWSWIRE
Caliway Announces enrollment in CBL-0204 Evaluating Efficacy of CBL-514
31 May 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.